Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck Gets First FDA Approval of Keytruda
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the walls of the chest and lungs.
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy.
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.
FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy
The Pharma Letter
2d
First FDA nod for Keytruda in MPM
Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...
11h
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
1d
Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential
Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Kentucky judge fatally shot
$230 million crypto theft
Russia threatens retaliation
Secret Service probing post
Three Mile Island to reopen
Boy kills bear, saves father
Cancels appearance w/ Duda
Families lose appeal
Body found in SUV
FCC chair denies Trump call
Man charged for threats
Rabies outbreak in seals
Hiker injured in bear attack
Collapse hazard recall
PGA welcomes LIV players
Recalling 449K+ vehicles
MS sheriff's office probe
Hold campaign event in MI
Vows to remain in race
Disney to stop using Slack
Stein's ballot bid rejected
Raises settlement offer
Brazil threatens daily fines
$3B for battery projects
COVID, Wuhan market link
FTC on privacy controls
To visit US next week
Overdose deaths drop in US
Related topics
Merck & Co.
Food and Drug Administration
Pembrolizumab
Feedback